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Background and Objectives. To evaluate the clinical
characteristics of patients with hematologic malig-
nancies developing a filamentous fungal infection
(FFI) and to define the prognostic factors for their
outcome.
Design and Methods. A retrospective study, con-
ducted on patients admitted to 14 Hematology divi-
sions of tertiary care or university hospitals, partic-
ipating in the GIMEMA Infection Program, over a
ten-year period (1988-1997). The study included
patients with hematologic malignancies and a his-
tologically and/or microbiologically proven or prob-
able FFI.
Results. We included 391 patients (male/female:
262/129, median age 49 years) with hematologic
malignancies (225 acute myeloid leukemia, 67
acute lymphocytic leukemia, 30 chronic myeloid
leukemia, 22 non-Hodgkin’s lymphoma, 12
myelodysplastic syndrome, 10 aplastic anemia, 7
Hodgkin’s disease, 8 chronic lymphocytic leukemia,
5 multiple myeloma, and 5 hairy cell leukemia) who
developed a proven FFI. Eighty percent of the
patients had been neutropenic for an average of 14
days before the infection, and 71% had an absolute
neutrophil count lower than 0.5×109/L at the time
of FFI diagnosis. The primary sites of infection were:
lungs (85%), nose and paranasal sinus (10%), and
other sites (5%). The diagnosis was made while still
alive in 310 patients (79%), and at autopsy in the
remaining 81 patients (21%). Chest X-ray was diag-
nostic in 77% of patients with pulmonary FFI, while
computed tomography (CT) scan of the thorax was
positive in 95% of cases. A significant diagnostic
advantage for CT scan was observed in 145 patients
who had both a chest X-ray and CT scan. Aspergillus
was identified as the cause of FFI in 296 patients,
Mucorales in 45 patients, Fusarium in 6 patients
and other filamentous fungi species in 4 patients,
while in a further 40 patients no agent was identi-
fiable. The overall mortality rate three months after
the diagnosis of FFI was 74%, and fungal infection
had been the cause of death in 51% of patients. 
Interpretation and Conclusions. Our retrospective
study shows that FFI still remains a life-threatening
complication in neutropenic patients. Despite
appropriate treatment, half of the patients die due
to this complication. The use of glucocorticoids and
recovery from neutropenia are the most important
prognostic factors. Mucorales infections are asso-
ciated with a significantly poorer prognosis than
those due to Aspergillus spp.
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The incidence of deep fungal infections inpatients with malignancies has increased dra-matically over the past decades. The majority of
these infections occur in patients with hematolog-
ic malignancies, particularly acute myeloid leukemia
(AML).1-5 This increase has been attributed to sever-
al factors: impairment of host defenses due to inten-
sive cytotoxic therapy, including blood stem cell
transplantation, ablative radiation therapy, use of
corticosteroids or cyclosporine, as well as the under-
lying hematologic malignancy.6-16
Until recently, Candida spp. were the most fre-
quent cause of invasive fungal infection in neu-
tropenic patients. Nevertheless, various autopsy
studies have shown that the incidence of Candida
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infections has remained substantially stable over
the years, while that of filamentous fungi (FFI) is
progressively increasing.17,18
Aspergillus spp. represent the main cause of FFI,
but emerging opportunistic fungal pathogens (i.e.
Fusarium spp.) have been reported over the last 20
years.2,10,19-21 In this retrospective analysis, we
reviewed the clinical features and their prognostic
relevance in 391 patients with hematologic malig-
nancies and a proven or probable FFI.
Design and Methods
Fourteen Hematology Departments from tertiary
care or university hospitals participated in this study.
Between January 1, 1988 and December 31, 1997,
we examined the clinical characteristics of patients
with hematologic malignancies and a documented
microbiological and/or histologic diagnosis of FFI.
Cases were defined using modifications of the
Mycoses Study Group Criteria.22 Proven FFI was
defined as follows: a) histo/cytopathologic findings
of filamentous fungi, associated with tissue dam-
age, even in the absence of microbiological isola-
tion. The observation of branched septate hyphae
was considered generically diagnostic for hyalohy-
phomycosis (i.e. aspergillosis, fusariosis), while that
of broad non-septate or rarely septate hyphae with
branches occurring at right angles were considered
diagnostic for infection by Mucorales; b) positive
culture obtained from a normally sterile site in
absence of possible contamination.
Probable FFI was defined as the isolation of fila-
mentous fungi from a non-sterile site (broncho-
alveolar lavage, one sample; sputum, two samples;
nasal swab, two samples), associated with clinical
signs of invasive FFI (pneumonia, cavitary infiltrates
or nodules, sinusitis). Radiologic findings such as
halo signs or air crescent signs on the chest X-ray
or CT-scan were also considered criteria for the
diagnosis. Patients with a radiologically or clini-
cally suspected FFI, in the absence of pathologic or
microbiological isolation, despite positive Asper-
gillus antigenemia, were not included in this study.
The clinical records of the enrolled patients were
examined. All the participating centers received a
form to be completed and sent to the co-ordinat-
ing center for each case of suspected, probable or
proven FFI during the study period. The centralized
data-base was constructed by assigning a number
to every case and transforming all the variables into
code. At the end of the study, all the centers were
asked to add, for each patient signaled, any new
data useful for examination. The following patients’
characteristics were taken into consideration: place
of birth and occupation, type and stage of hema-
tologic malignancy, clinical signs, symptoms and
site of infection, radiologic findings, laboratory data
[i.e. neutropenia (neutrophil count <1×109/L),
microbiological isolates], treatment received, cause
of death, autopsy findings. Death due to FFI was
defined as occurring in the presence of microbio-
logical, histologic, or clinical evidence of active fun-
gal infection. Data from the episode of FFI and fol-
low-ups at 3 and 6 months were collected.
Statistical methods
Potential prognostic indicators predicting the
outcome of FFI were analyzed by the χ2 test and
the factors significantly associated in the univari-
ate analysis were included in a logistic regression
model to analyze their independent role. The Cox
proportional-hazard model was used for multivari-
ate assessment of the relative risk of death during
infection, after adjustment for potentially con-
founding factors. The two-tailed test of signifi-
cance at p<0.05 was used to determine statistical
significance.
Results
Among patients with hematologic malignancies,
449 episodes of FFI were reported by the 14 par-
ticipating divisions of hematology during the study
period. Fifty-eight episodes were excluded from the
study because the diagnosis of FFI was based only
on clinical evidence. The 391 evaluable patients
had an age ranging between 12 and 84 years
(median 49 years), 262 were male and 129 were
female. Two hundred and thirty-seven patients
(62%) had a proven FFI, while 154 (38%) had a
probable FFI. Overall, most FFI (222 episodes,
56.7%) were documented in patients undergoing
first treatment for their hematologic malignancy.
Table 1 shows the underlying disease and the
treatment phase at the time of FFI diagnosis. Acute
leukemia was diagnosed in 75% of cases (292
patients), AML being the most frequent malignan-
cy (225 patients, 57.5%). The overall incidence of
FFI in patients with adult acute leukemia (over 12
years of age) registered by the participating cen-
ters was 6.5% (292 FFI /4448 new cases of acute
leukemia). The lack of a common national register
for hematologic malignancies other than acute
leukemia makes it impossible to calculate the inci-
dence of FFI in such pathologies.
Risk factors for FFI prior to diagnosis
None of the patients included in this study had
a previous history of FFI. The FFI had been preced-
ed by chemotherapy in 355 patients (90%), while
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28 (7%) had not received any treatment during the
previous 3 months either because not indicated 
(e.g. myelodysplastic syndromes) or due to their
poor performance status. In 5 patients with aplas-
tic anemia the immunosuppressive treatment was
only cyclosporine; 3 further patients with hairy cell
leukemia (HCL), chronic myeloid leukemia (CML),
and non-Hodgkin’s lymphoma (NHL) received only
α-interferon. Before the diagnosis of FFI, 311
patients (80%) had been neutropenic (absolute
neutrophil count [ANC] lower than 0.5×109/L) for
a median of 14 days (range 1-250). At the diagno-
sis of FFI, 277 patients (71%) had an ANC lower
than 0.5×109/L, and 221 patients (57%) had an
ANC lower than 0.1×109/L. Broad-spectrum antibi-
otics (β-lactam plus an aminoglycoside with or
without a glycopeptide) had been administered to
311 patients (80%) for a median of 11 days (range
1-60). A clinically suspected or microbiologically
documented bacterial infection preceded FFI in 156
cases (40%). In particular, a bacteremia was diag-
nosed in 55 cases (30 Gram positive, 22 Gram neg-
ative, and 3 polymicrobial).
Antifungal prophylaxis was administered to 313
patients (80%). Oral non-absorbable polyenes,
amphotericin B (amB) or nystatin were used in
141/391 cases (36%); systemic prophylaxis, with
fluconazole, 150-300 mg/daily, or itraconazole,
200-400 mg/daily, had been employed in 109 and
41 cases, respectively (38%). Other types of pro-
phylaxis were employed in 22 cases [aerosol-
administered amB, 6 cases; low doses (<0.5
mg/kg/day) i.v. amB, 10 cases; ketoconazole, 6 cas-
es]. The median duration of prophylaxis before FFI
was 20 days (range 1-100).
Two hundred and twenty-five patients (57%) had
been treated with steroids, using a median equiv-
alent dose of 6-methylprednisolone of 60 mg dai-
ly (range 20-120), for a median of 20 days (range
1-370) and a median total dose of 875 mg (range
48-24,000). In the majority of cases, steroids were
administered as part of the treatment of chemo-
therapy or during the transplant procedure. Con-
sidering other known risk factors, 45 patients
(13%) had diabetes and 18 patients (4%) had
undergone a recent surgical procedure. Nineteen
patients (4.8%) developed FFI despite protective
isolation in laminar airflow or hepa-filtered rooms.
Clinical presentation
Sites of fungal infection are illustrated in Table
2. Primary sites of infection were defined as those
where the earliest and/or major signs or symptoms
of disease appeared, and secondary sites were
those following dissemination. In 7 patients the
primary site of infection was not identified,
because the infection presented with multiple
localizations. Table 3 illustrates signs and symp-
toms according to the infected sites. Fever, with a
median temperature of 38.4°C at presentation, was
the most frequent symptom (80% of episodes).
Twenty-nine patients were asymptomatic and
diagnosis was made only at autopsy.
Diagnostic procedures
A diagnosis of FFI was made in vivo in 310
patients (79%), while in 81 patients (21%) the clin-
ical suspicion of FFI was confirmed at autopsy. Table
4 reports the main diagnostic procedures employed
and the percentage of positive results, according to
infected sites. CT scan of the chest had a higher
efficacy than standard chest X-ray (94.5% vs.
864
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Table 1. Hematologic malignancy and phase of treatment of 391 cases of FFI.
AML ALL NHL HD CML MM CLL Aplasia MDS HCL Total (%)
First induction 151 39 10 4 8 3 3 / 3 1 222 (57)
Re-induction 24 16 3 / / / / / / / 43 (11)
Consolidation 20 3 1 / / / / / / / 24 (6)
Maintenance 2 / / / 3 / 2 / / / 7 (2)
Autologous BMT 7 2 / 2 2 1 / 1 / / 15 (4)
Allogeneic BMT 3 3 1 / 13 1 / 1 1 / 23 (6)
Salvage 7 3 6 1 2 / 1 / 1 / 21 (5)
Immunosuppression / / 1 / 1 / / 5 / 1 8 (2)
None 11 1 / / 1 / 2 3 7 3 28 (7)
Total 225 67 22 7 30 5 8 10 12 5 391 (100)
AML = acute myeloid leukemia; ALL = acute lymphoid leukemia; NHL = lymphoma; HD = Hodgkin’s disease; CML = chronic myeloid leukemia; MM = multiple 
myeloma; CLL = chronic lymphocytic leukemia; Aplasia = aplastic anemia;  MDS = myelodysplastic syndrome; HCL = hairy cell leukemia; BMT = bone marrow transplantation.
76.7% respectively) in patients with pulmonary FFI.
Among 143 patients who underwent both investi-
gations, with no more than 5 days elapsing between
the two (median 3 days), CT scan was positive in
135 patients (94%) and X-ray in 124 patients (87%)
(O.R. 2.59, 95%C.I. 1.03-6.70; p<0.02). Seven of 11
patients with a negative X-ray and a positive CT
scan had a peripheral pulmonary lesion, while 4
patients had a retro-cardiac infection. Ten of these
patients had a negative chest X-ray and positive CT
scan of the chest on the same day. No differences
in documenting single or multiple lung lesions were
found between X-ray and CT scan. The presence of
a cavitation was demonstrated in 5% of X-rays (12
patients) and 13% of CT scans (18 patients). Bron-
choalveolar lavage (BAL) culture was positive in 80
out of 128 examinations (62%). In 48 patients with
a negative BAL, diagnosis was made following
surgery in 13 patients and at autopsy in 16 patients.
FFI was documented in the sputum in 15 cases, by
histology of tissues other than the lungs (2 cases)
and by culture of pleural effusion (2 cases), per-
formed after BAL.
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Table 2. Sites of fungal infection (in vivo or at autopsy).
Primary (%) Secondary (%)* Total (%)
Lung 321 (82.1) 11 (2.8) 332 (84.8)
Nose 23 (5.9) 16 (4) 39 (9.9)
Sinus 21 (5.4) 31 (7.9) 52 (13.3)
Bowel 4 (1) 5 (1.2) 9 (2.2)
Blood 4 (1) 3 (0.8) 7 (1.7)
Skin 3 (0.8) 8 (2) 11 (2.7)
Orbit 3 (0.8) 3 (0.8) 6 (1.5)
CNS 3 (0.8) 34 (8.7) 37 (9.4)
Oral cavity 1 (0.2) 1 (0.2) 2 (0.5)
Liver 0 6 (1.5) 6 (1.5)
Myocardium 1 (0.2) 3 (0.8) 4 (1)
Middle ear 0 1 (0.2) 1 (0.2)
Kidney 0 2 (0.5) 2 (0.5)
Spleen 0 5 (1.2) 5 (1.2)
Multiple at diagnosis° 7 (1.8) 0 7 (1.7)
*Some patients had two or more involved sites. °Patients had more than 2
involved sites and it was not possible to identify the primary site.
Table 3. Signs and symptoms of the patients at the diag-
nosis by site of infection.
Sign/symptom N %
Pulmonary localization 332
Fever 269 81
Cough 235 71
Chest pain 153 46
Dyspnea 144 43
Hemoptysis 24 7
Pneumothorax 5 1.5
Sino-nasal localization 91
Fever 63 69
Facial edema 77 85
Nasal obstruction 74 81
Facial pain 52 57
Rhinorrhea 33 36
Epistaxis 7 8
Palate destruction 4 4
Central nervous system involvement 37
Fever 15 40
Cerebral hemorrhage 18 49
Hemiplegia 7 19
Ptosis 4 11
Epilepsy 2 5
Gastro-intestinal tract 9
Fever 6 67
Abdominal pain 4 44
Diarrhea 8 89
Rectorrhagia 1 1
Asymptomatic 22
Total 469*
*more sites infected in the same patient.
Table 4. Radiological and microbiological procedures used
to diagnose FFI in respect of the main sites involved.
% Performed Positive/performed % Sensitivity
Pulmonary localization (no. 332)
Chest X-ray 98 251/327 77
Single lesion 117
Multiple lesions 134
Chest CT 44 138/146 94
Single lesion 63
Multiple lesions 75
Broncho-alveolar lavage culture 38 80/128 62
Surgical specimens 18 40/51 87
Sputum 72 139/241 58
Nasal swab 56 61/191 32
Brain localization (no. 37)
Cerebral CT 65 21/24 88
Surgical specimens 8 2/3 66
Sino-nasal localization (no. 58*)
Cranial CT 50 25/29 86
Nasal swab 71 35/41 85
Surgical specimens 19 11/11 100
Serology
Antigen 29/90 32
Antibody 2/50 4
Cutaneous biopsy 12/12 100
Bowel resection 1/1 100
Autopsy specimen 28 106/111 96
*33 patients had both nasal and sinus localizations.
Lung biopsy was performed in 51 patients (42
trans-bronchial, 11 trans-thoracic needle and 8
open lung biopsies). This procedure was positive in
78.4% of cases: 21 trans-bronchial (65.6%), 11
trans-thoracic (100%) and 8 open lung biopsies
(100%).
Brain aspergillosis was suspected due to neuro-
logical signs in 37 patients and CT scan was com-
patible with fungal abscesses in almost all the cas-
es it was performed (21/24, 87%). Cerebral biopsy
was performed in 3 patients only and was positive
in 2 of them. The diagnosis of central nervous sys-
tem (CNS) FFI was confirmed at autopsy in 35
patients, including the patient with a negative CNS
biopsy. All but one patient died within a few weeks
from the onset of neurological signs.
Biopsy of sino-nasal tissues (11 cases) or of skin
lesions (13 cases) was diagnostic in all cases exam-
ined. Interestingly, a localized bowel Aspergillus
fumigatus infection was diagnosed at surgical
debridement in one patient with intestinal obstruc-
tion. Histologic specimens (lung, central nervous
system, sino-nasal, skin and bowel) were positive
for FFI in 67 (75%) of 89 patients (23%). None of
the patients had complications following the diag-
nostic procedure.
Serum Aspergillus antigenemia was studied in 90
patients using a latex agglutination assay of galac-
tomannan and was positive (at least 2 times) in 29
cases (32%). In 27 patients (93%) the antigen was
detected after the pulmonary infection had been
diagnosed or suspected. Serology for Aspergillus
was performed in 50 cases and was positive in 2
cases (4%).
Etiology
Table 5 reports the filamentous fungi identified
as causal agent in 391 cases of FFI. Filamentous
fungi were identified only histologically in 169 cas-
es, in the absence of a positive culture of histolog-
ic specimens. However, on the basis of histo-micro-
biological findings, hyalo-hyphomycetes were
identified in 40 cases, and Mucorales in 28 cases.
Aspergillus was the agent of FFI most frequently
isolated (296 cases; 76%) and of 194 types of
Aspergillus isolates, Aspergillus fumigatus was the
main agent, responsible for 53% (102 episodes) of
infections. Mucorales were isolated in 11.5% of
cases (45 episodes), and FFI were sustained by oth-
er filamentous fungi (Fusarium spp., Scedosporium
apiospermum/Pseudallescheria boydii, Scopulari-
opsis brevicaulis, Acremonium spp) in a further 10
cases. The ratio Aspergillus/Mucorales was 6.9/1.
No relationship was shown between clinical char-
acteristics and outcome of infections due to the
different Aspergillus spp. identified (A. fumigatus, A.
flavus, and A. terreus).
Treatment and outcome
Antifungal treatment was administered to 341
patients (87%) and was started empirically in 274
patients (81%) with persistent fever after 72 hours
of intravenous broad spectrum antibiotics. Deoxy-
cholate amB was employed in 285 cases (73%) at
a median dose of 1 mg/kg/daily (range 0.6-1.6).
The total median dose of amB was 15 mg/kg (range
0.50-100) for a median of 18 days (range 1-200).
In 51 patients other antifungal drugs were added
to or followed amB treatment [intravenous 5-fluo-
cytosine (6 cases), oral itraconazole (39 cases), and
ketoconazole (6 cases)]. Eighteen patients switched
from amB to liposomal amB (L-amB) because of
renal impairment (median daily dose: 2 mg/kg). In
56 cases (14%) FFI was initially treated with drugs
other than amB: L-amB was given to 23 patients
(median daily dose 2 mg/kg, range 1-3) for a medi-
an of 20 days (2-150) and a median cumulative
dose of 18.5 mg/kg (4-44.2), oral itraconazole to 18
patients (400-600 mg/day) for a median of 31 days
(8-200), and intravenous fluconazole to 15 patients
(600-800 mg/day) for a median of 14 days (2-60).
Granulocyte transfusions from family donors were
given to 8 neutropenic patients whose fever was
unresponsive to antifungal therapy. Only 1 of these
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Table 5. Etiological agents of 391 cases of FFI.
N %
Hyalohyphomycetes* 40 10.2
Aspergillus 296 75.7
Aspergillus spp 102 34.5
Aspergillus fumigatus 108 36.5
Aspergillus flavus 58 19.6
Aspergillus terreus 15 5
Aspergillus niger 7 2.4
Aspergillus versicolor 4 1.4
Aspergillus glaucus 1 0.3
Aspergillus nidulans 1 0.3
Mucorales° 45 11.5
Mucorales spp 28 62.2
Mucor spp 10 22.2
Rhizopus spp 4 8.8
Cunninghammella 2 4.6
Absidia corymbifera 1 2.2
Fusarium spp 6 1.5
Scedosporium apiospermum/Pseudallescheria boydii 2 0.4
Scopulariopsis brevicaulis 1 0.2
Acremonium spp 1 0.2
*Observation at histo/cytopathology of branched septate hyphae. 
°Diagnosis on histologic or microbiological specimens.
patients improved after transfusion. Ninety-six
neutropenic patients (24%) received growth fac-
tors (rhG-CSF, 84 patients and rhGM-CSF, 12
patients). The use of growth factors was based on
personal evaluation of physicians of each center.
The treatment resulted in disappearance of fever
and improvement of clinical status in 164 patients
(42%). The remaining 227 cases (58%) progressed.
Two hundred and ninety patients (74%) died with-
in 90 days after diagnosis of FFI: 83 patients (21%)
because of progression of the underlying hemato-
logic malignancies, 198 (51%) of FFI and 9 (2%)
because of bacterial infection (septic shock caused
by Gram-negative bacilli in 7 cases and bacterial
pneumonia in 2 cases). Fifty patients (13%) did not
receive any antifungal treatment. Forty-one died
from FFI (82%), 6 patients (12%) died from malig-
nancy and one patient (2%) from bacterial infec-
tion. In spite of the absence of antifungal treat-
ment, 2 patients improved from FFI after a recov-
ery of neutrophil count. Autopsy was performed in
111 patients. Ninety-six percent of patients showed
findings consistent with active FFI.
Survival
Table 6 shows factors identified by univariate and
multivariate analysis that correlated with a nega-
tive outcome of the infection. Patients dying with-
in 5 days from the start of antifungal treatment
were excluded from analysis. Older age, use of cor-
ticosteroids, an ANC lower than 0.1×109/L at the
diagnosis of FFI, lack of recovery from aplasia, mul-
tiple pulmonary localizations of infection, Muco-
rales as agents of FFI, absence of treatment or use
of fluconazole and a total cumulative dose of amB
lower than 25 mg/kg negatively influenced the
outcome of FFI. Other parameters such as sex,
underlying hematologic disease (acute leukemia vs.
all other diseases), stem cell transplantation, dia-
betes, use of growth factors, previous use of broad-
spectrum antibiotics, nasal colonization, primary
site of infection, antifungal prophylaxis and fever
had no prognostic impact.
The multivariate analysis showed that the use of
steroids (OR 1.98, 95%CI 1.13-3.48), Mucorales
etiology (OR 3.54, 95%CI 1.51-8.32) and the lack
of neutrophil recovery (OR 0.28, 95% CI 0.16-0.49)
correlated significantly with death from FFI.
Discussion
In this study we have enrolled the largest ever-
collected series of proven FFI in patients with
hematologic malignancies. At least 6.5% of
patients developed FFI during the course of acute
leukemia, and in particular acute myeloid leukemia
was associated with the highest risk of FFI. Con-
sidering the retrospective nature of the study and
the inclusion of only microbiologically and/or his-
tologically documented cases, the real incidence
of FFI in acute leukemia patients is probably sig-
nificantly higher. We could not evaluate the inci-
dence of documented FFI in malignancies other
than leukemia during the study period because of
the lack of a registry of other hematologic diseases.
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Table 6. Univariate and multivariate analysis of patients’
characteristics in relation to fungemic death.
Characteristics Death from FFI/total Univariate Multivariate
(%) analysis analysis
Sex
male 132/262 (50) n.s.
female 66/129 (51)
Age
<30 29/80 (36) 1.00
30-60 117/220 (53) 0.007 1.86 (0.92-3.75)
>60 53/91 (58) 2.14 (0.92-4.98)
Diabetes*
yes 26/45 (50) n.s.
no 152/306 (58)
Corticosteroids
yes 125/225 (56) 0.024 1.98 (1.13-3.48)
no 73/166 (44) 1.00
Neutropenia at diagnosis
<0.1×109/L 126/221 (57) 0.01 1.00
<0.5×109/L 22/56 (39) 0.70 (0.39-1.27)
<1×109/L 16/34 (47) 1.00
Neutrophil recovery
yes 63/166 (38) 0.0001 0.28 (0.16-0.49)
no 101/144 (70) 1.00
Growth factors
yes 45/96 (47) n.s.
no 153/295 (52)
Chest CT-scan
single lesion 18/63 (29) 0.019
multiple lesions 36/75 (48)
Etiology
Aspergillus spp. 144/296 (49) 0.002 1.00
Mucorales 33/45 (73) 3.54 (1.51-8.32)
Prophylaxis
yes 158/313 (50) n.s.
no 40/78 (51)
Therapy
none/fluconazole 47/65 (72) 0.0002 1.00
AmB/itraconazole 154/326 (47) 0.92 (0.41-2.09)
AmB treatment°
<25 mg/kg 93/184 (51) 0.012
>25 mg/kg 22/67 (33)
*Information was not available for 40 patients; °33 patients died within 5 days
of beginning treatment and were excluded from the evaluation.
Interestingly, most of the patients (57%) devel-
oped FFI following the first course of chemothera-
py. It is well known that exposure to Aspergillus is
almost universal and in immunocompetent subjects
macrophages and polymorphonuclear leukocytes
are an effective defense system.23 Impairment of
the immune response due to the underlying hema-
tologic malignancy or the immunosuppressive ther-
apy may play a role in the onset and diffusion of FFI,
during the early phases of the treatment in colo-
nized patients.8 The risk of developing FFI has been
reported to increase progressively with the duration
of neutropenia, reaching a plateau of 70% among
patients neutropenic for more than 34 days.24 On
the other hand, it is possible that the high inci-
dence of FFI in acute myeloid leukemia patients is
due to the fact that these patients have a prolonged
hospitalization, particularly those who are under-
going first induction chemotherapy. The majority of
our patients had a profound neutropenia and had
had a prolonged neutropenic phase prior to the
diagnosis of FFI. Corticosteroids are an additional
important risk factor:11,13 in our series corticos-
teroids were used by 57% of patients at a relative-
ly high dose as part of the chemotherapy regimen
or as treatment for graft-versus-host disease. Per-
haps it would be helpful to reduce the use of cor-
ticosteroids whenever this is possible. Antifungal
prophylaxis is widely employed in patients with
acute leukemia but its real benefits and the proper
schedule are still controversial.25 We cannot com-
ment on the role of FFI prophylaxis because only
12% of our patients received a drug active against
Aspergillus (itraconazole or i.v. amB).
Our study clearly shows that lung and nasal sinus-
es are the most frequent sites of FFI, which corre-
lates with the modality of transmission of infection.
Signs and symptoms were various, but fever and
pain at the site of infection were present in almost
all patients. It is remarkable that 22 patients were
completely asymptomatic and that their infection
was diagnosed at autopsy. It has been reported that
FFI develops in about 20% of patients with acute
leukemia,17,18 but the diagnosis can be proven in only
30% of them. Invasive procedures are frequently
limited by the bad general condition of the patients
or because of thrombocytopenia. Both invasive and
non-invasive procedures allowed the diagnosis of
FFI in a relatively high percentage (79%) of patients
while alive. However, because of  the retrospective
nature of the study and the relatively low number
of autopsies performed, these data may represent an
overestimate of the real diagnostic power of the
current procedures employed. Although our data
cannot be used to evaluate the sensitivity and speci-
ficity of single diagnostic procedures, we observed
a different yield of the diagnostic techniques in rela-
tion to the sites involved.
Radiological exams such as standard chest X-ray
and early CT scan were almost routinely employed.
As recently reported in different studies, tomogra-
phy pictures characterized by a mass-like infiltrate
with a surrounding halo of ground glass attenua-
tion or by the air crescent sign compatible with pul-
monary cavitation can be considered diagnostic of
a pulmonary FFI.26,27 We observed that in patients
with lung involvement, who had both chest X-ray
and CT scan performed almost simultaneously, CT
scan gave a diagnostic advantage over the stan-
dard lung X-ray. Bronchoscopy with BAL is lately
being frequently employed due to the low incidence
of complications. However in the literature, the sen-
sitivity of BAL in the diagnosis of FFI has a wide
range, from 0 to 80%.28-32 Taking into account the
retrospective nature of our study and the diagnos-
tic criteria of FFI adopted, the 62% sensitivity of
BAL in our experience was higher than other pub-
lished results. False negative cases were probably
due to variables such as the presence of peripheral
lesions not attainable by bronchoscopy, to a perile-
sional fibrous annulet preventing the passage of
hyphae into the bronchial system, or due to early
execution of BAL, with later positive culture of oth-
er biological samples. Surgical biopsies represent-
ed the most useful tool for the diagnosis of FFI. Due
to the critical conditions of the patients, surgery
was performed in our study in only 23% of patients.
Our work confirms data by Kami et al.33 on the
low sensitivity (32%) of Aspergillus galactomannan
serum detection by latex agglutination tests. Anti-
genemia also showed a poor diagnostic value, con-
firming only documented diagnosis of Aspergillosis.
Aspergillus spp. were responsible for 76% of all FFI,
followed by Mucorales (11.5%). Histology was diag-
nostic for 10% of unspecified FFI, and other agents
such as Fusarium, Acremonium, Scedosporium, and
Scopulariosis were responsible for 2.5% of all doc-
umented infections. It is remarkable that a great
number of infections due to Mucorales (13
episodes) were reported over a two-year period by
one center and that the source of infection was
never identified, although an epidemic could not
be excluded.
To date, amB has been considered the drug of
choice for the treatment of FFI.34-36 The antifungal
treatment was based on the experience of differ-
ent participating centers. In the great majority of
patients, amB (deoxycolate or rarely liposomal) and
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in some cases itraconazole, was the first-line treat-
ment. Only a few asymptomatic cases diagnosed by
autopsy did not receive any therapy. The treatment,
frequently started empirically, was effective in 42%
of patients, while about 50% of patients died from
FFI within 90 days of diagnosis. The univariate
analysis showed that the prolonged use of amB
was correlated with recovery from the infection.
However, we cannot exclude that the correlation
between the high cumulative dose of amB and the
good outcome of patients was simply due to bet-
ter clinical conditions and prolonged survival.
At univariate analysis an absolute neutrophil
count <0.1×109/L at diagnosis of FFI was associat-
ed with a poor survival, and, at multivariate analy-
sis, persistent neutropenia was associated with a
significantly lower probability of survival at three
months from the diagnosis of FFI. Some studies
recently suggested that the use of growth factors,
to aid rapid recovery from aplasia and to increase
the fungicidal activity of monocytes, associated
with granulocyte transfusions collected from rhG-
CSF-primed healthy volunteers, could support anti-
fungal treatment and stimulate recovery from
infection.37 However, the use of growth factors was
not associated with a statistically significant
improvement of survival.
In conclusion, our study shows that patients with
acute myeloid leukemia are at high risk of devel-
oping FFI. These infections occur during the first
phases of the disease and despite prompt and time-
ly antifungal therapy the outcome is strongly
affected by the degree and duration of neutrope-
nia. The appropriate use of diagnostic techniques
is critical for the timely identification of infections.
Future studies should focus on the prevention of
environmental and host factors.
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